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1. Introduction
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes is a
series of Editorials, which are published on a biannual basis by the Editorial Board of the Medicinal
Chemistry section of the journal Molecules. In these Editorials, we highlight, in brief reports of about
one hundred words, a number of recently published articles that describe crucial findings such as the
discovery of novel drug targets and mechanisms of action or novel classes of drugs, and may inspire
future medicinal chemistry endeavors devoted to address prime unmet medical needs.
2. An Allosteric Inhibitor with the Most Complex Mode of Action to Combat Tuberculosis
Highlighted by Diego Muñoz-Torrero
New antitubercular agents with novel mechanisms of action are needed to cope with the
steady rise in multidrug resistance. Phenotypic screening of a diversity-oriented synthetic
library has led to the identification of (2R,3S,4R)-3-[2′-fluoro-(1,1′-biphenyl)-4-yl]-4-(hydroxymethyl)
azetidine-2-carbonitrile (BRD4592), which kills Mycobacterium tuberculosis (Mtb) from a diverse panel
of clinical isolates, including drug-resistant strains [1]. BRD4592 hits the essential metabolic enzyme
tryptophan synthase (TrpAB), which contains two α and two β subunits that catalyze the penultimate
and last steps of L-tryptophan biosynthesis. BRD4592 is an allosteric inhibitor of α and β subunits.
By binding at the α-β interface along the tunnel that connects both subunits, BRD4592 blocks shuttling
between the two active sites of indole produced at the α subunit to be converted into L-tryptophan at
the β subunits. Moreover, it stabilizes crucial enzyme states, including the enzyme-product complex,
thereby preventing catalytic cycling. The unique multicomponent mode of action of BRD4592 will
hopefully inspire the design of a new generation of highly potent allosteric Mtb TrpAB inhibitors.
3. Inhaled Selective Indazole Ether-Based Glucocorticoid Receptor Modulators: A Novel
Treatment Strategy for Asthma and Chronic Obstructive Pulmonary Disease?
Highlighted by Arduino A. Mangoni
The global health burden of asthma and chronic obstructive pulmonary disease (COPD)
is increasing despite preventive strategies and available inhaled anti-inflammatory therapies.
The latter, particularly glucocorticoids, are associated with local and systemic adverse effects.
Hemmerling et al., following the discovery of indazole ethers as potent nonsteroidal glucocorticoid
receptor modulators, implemented a soft-drug strategy with further optimization that led to a
lead compound, 3-(5-((1R,2S)-2-(2,2-difluoropropanamido)-1-(2,3-dihydrobenzo-[b][1,4]dioxin-6-yl)
propoxy)-1H-indazol-1-yl)-N-((R)-tetrahydrofuran-3-yl)benzamide, with high selectivity for the
progesterone receptor [2]. In pharmacokinetic studies in rats, this compound showed,
when administered by inhalation, slow dissolution, low volume of distribution, and relatively
high lung retention. In a rat model of Sephadex-induced airway inflammation, this compound
effectively inhibited lung edema, particularly when pre-dosed 9 h prior to challenge. Pending further
pharmacodynamic/pharmacokinetic characterization and optimization, this study might pave the
way for the development of a new class of drugs for asthma and COPD.
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4. The Advancement of Developing Potent Proteolysis-Targeting Chimeras (PROTACs) in
Anticancer Drug Discovery
Highlighted by Hong Liu
PROTACs are a novel class of heterobifunctional molecules designed to recruit a target protein
to an E3 ubiquitin ligase complex, enabling following poly-ubiquitination and degradation of
the target. PROTACs are characterized by inhibiting the activity of specific proteins that drive
tumor growth by targeted degradation, thus they may be useful in the drug-resistance of cancer.
Recently, PROTACs designed to degrade the BRD4 protein have been reported by several
labs. In 2017, Alessio Ciulli et al. [3] revealed the first ternary crystal structure of the PROTAC
molecule (BRD4 degrader MZ1) with the target protein (BRD4 bromodomain) and E3 ubiquitin
ligase (human VHL), which provides structural insights into how PROTACs induce target-specific
protein–protein interactions of the target protein with an E3 ligase to form the isoform-specific ternary
complexes for selective degradation. At the same time, Shaomeng Wang et al. [4] reported a new class
of PROTAC inducing BRD4 degradation, which structurally combined BET4 inhibitor HJB97 with
thalidomide as the cereblon ligand. The most potent inhibitor (BETd-260) of this series effectively
degrades BRD4 protein with an IC50 value of 30 pM in the RS4;11 leukemia cell line with a good
selectivity over BRD2 and BRD3, and achieves extremely excellent RS4;11 cell-growth inhibitory
activity (IC50 = 51 pM), and shows remarkable in vivo tumor suppression activity against RS4;11
xenograft tumors with 5 mg/kg IV dose without apparent body weight change. Although now the
poor oral PK properties appear to be the biggest potential limitation of PROTACs, all these data above
indicate that PROTACs are a most promising strategy of targeted protein degradation, thus making it
a potential targeted therapeutic method for cancer.
5. Dyrk1 Inhibition Improves Alzheimer’s Disease-Like Pathology
Highlighted by Christopher Hulme
The dual-specificity tyrosine phosphorylation-regulated kinase-1A (Dyrk1a) is a protein kinase
that phosphorylates the amyloid precursor protein (APP) and tau and thus represents a link between
two key proteins involved in AD pathogenesis. As such, inhibition of Dyrk1a and restoration of its
activity to normal levels in AD patients is postulated to alleviate both major aggregates in AD—amyloid
plaques and insoluble tau aggregates—a unique, and the only pleiotropic targeting approach in the
aggregation field. Results presented by Oddo et al. reveal the discovery of the first selective, brain
penetrant Dyrk1a inhibitor that enticingly significantly reduces both Aβ42 levels and insoluble tau
aggregates, simultaneously improving cognition, in well-tolerated fashion, during an 8-week study in
10 month old 3xTg-AD female mice [5].
6. The ProTide Prodrug Technology from the Concept to the Clinic
Highlighted by Jarkko Rautio
The ProTide prodrug technology that was discovered by Prof. Chris McGuigan is an
efficient strategy to enable intracellular delivery of nucleoside analogue monophosphates and
monophosphonates [6]. Nucleoside analogs, which have shown to be effective against cancer and
various infections, must undergo the stepwise addition of phosphate groups mediated by cellular
kinases to form the corresponding active nucleoside triphosphates. To circumvent the first rate-limiting
phosphorylation step, nucleoside analogs are frequently dosed as their monophosphorylated forms
or are structured to contain a phosphonate form. In ProTide strategy, the hydroxyl groups of the
monophosphate or monophosphonate groups are masked with an aromatic and an amino acid ester
promoieties. Lipophilic prodrugs are efficiently delivered to the cytosol of hepatocytes where the
corresponding active triphosphate forms are formed after several consecutive enzymatic cleavage and
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addition reactions, respectively. To date, two ProTide prodrugs, tenofovir alafenamide and sofosbuvir,
have been approved by the FDA. In addition, several other ProTide prodrugs have been tested in
clinical trials. Those include GS-5734, which is being developed as a treatment of Ebola and other
emerging viruses, and is engaged in Phase II clinical trials. This review thoroughly summarizes the
applicability of the ProTide prodrug technology in the improvement of drug delivery and efficacy.
7. Understanding and Sensitizing Density-Dependent Persistence to Quinolone Antibiotics
Highlighted by Rafik Karaman
A novel approach to make bacteria more sensitive to the antibacterial agent quinolones, which
are utilized in the treatment of infections caused by Escherichia coli and Staphylococcus aureus, has been
discovered by MIT researchers. The new approach has succeeded to overcome major limitations of
these antibacterial agents which involve failures when used to treat infections characterized with a
very high density of bacteria [7].
In 2011, Collins’s group found that the ability of the aminoglycoside antibiotics to kill
drug-resistant bacteria can be increased by delivering a sugar along with the drug. The sugar helps to
accelerate the metabolism of the bacteria, thus enabling the bacteria to undergo cell death in response
to the DNA damage caused by the drug.
Due to side effects associated with the use of aminoglycosides, the group switched their research
towards boosting the effectiveness of quinolones. With quinolones, the researchers found that a
combination of a sugar and a terminal electron acceptor is a must to achieve the desired effect [7].
It is believed that this new approach has great potential to increase the effectiveness of existing
antibacterials to kill bacteria that cause chronic infections.
8. Durable Antibiotic to Overcome Vancomycin Resistance with Synergistic Mechanisms
Highlighted by Maria Emília de Sousa
The spread of resistant bacteria, leading to untreatable infections, is a global threat. Several
approaches to overcome antibacterial drug resistance have disclosed new antibiotics acting by multiple
mechanisms. The research group of D. Boger [8] from the Scripps Research Institute in San Diego,
California, described an approach to design durable antibiotics targeting vancomycin-resistant
Enterococci (VRE), endowed with multiple synergistic mechanisms of action. Inspired by the
nonselective membrane disruption induced by quaternary ammonium salts, the group introduced
an alternative C-terminal peripheral modification at vancomycin analogs that induced membrane
permeability without membrane depolarization or cell wall lysis. This approach culminated in an
antibiotic 25,000-fold more potent than vancomycin against VRE with three independent mechanisms
of action: membrane permeability induced by the C1 quaternary ammonium salt, inhibition of bacterial
cell wall biosynthesis by direct transglycosylase inhibition caused by the (4-chlorobiphenyl)methyl
modification and only one mechanism was dependent on D-Ala-D-Ala/D-Ala-D-Lac binding, the
molecular basis of resistance to vancomycin. Moreover, this new vancomycin analog reduced
susceptibility to resistance and represents a remarkable accomplishment in the total synthesis of
glycopeptides. A remarkable example of multiple synergistic medicinal chemistry approaches!
9. Brain-Selective Estrogen Therapy via a Unique Bioprecursor Prodrug Approach
Highlighted by Katalin Prokai-Tatrai
In order to exploit the vast array of beneficial effects of 17β-estradiol (E2) in the brain,
brain-selective delivery of the hormone is needed to ensure therapeutic safety and efficacy.
This elusive goal may now finally be accomplished in clinical settings by discovering that
10β,17β-dihydroxyestra-1,4-dien-3-one (DHED) is rapidly converted to E2 in the brain with
extraordinary selectivity compared to the rest in the body. Therefore, DHED is a brain-selective
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bioprecursor prodrug of E2 that utilizes an NAD(P)H-dependent and brain-specific enzyme-catalyzed
process to produce the hormone within the brain [9]. DHED is obtained by a simple stereoselective
oxidation of the phenolic A-ring of E2, resulting in significantly improved physicochemical properties
in the context of brain uptake from the circulation. With a series of in vitro and in vivo studies in
preclinical animal models, the tremendous translational potential of DHED owing to its unprecedented
and distinguishing feature in terms of brain-selective delivery of the parent hormone have been
convincingly shown [9].
10. New Avenues in the Bacterial Mass Bioproduction of Molecules with ‘Improved’
Characteristics
Highlighted by Jean-Marc Sabatier
The work by Chiang and collaborators [10] describes for the first time the biotransformation of
a crude extract of soy isoflavones containing antioxidant glycosides daidzin and genistin, using the
bacterium Escherichia coli expressing the recombinant tyrosinase from Bacillus megaterium. Interestingly,
the main products of biotransformation were characterized as 3′-hydroxyisoflavone glycosides
(i.e., 3′-hydroxydaidzin and 3′-hydroxygenistin) and showed respectively 120- and 72-fold superior
2,2-diphenyl-1-picrylhydrazyl free radical scavenging activities compared to their daidzin and
genistin precursors. Therefore, apart from reporting on the successful bioproduction (and potential
antioxidant/reductant applications) of two 3′-hydroxyisoflavone glycosides, this innovative work
potentially paves the way to the mass bioproduction of other interesting compounds/derivatives with
some 'optimized' functional characteristics.
11. Fighting the War against Type 2 Diabetes
Highlighted by Carlo Siciliano
Compounds stimulating insulin production represent promising candidates for the treatment
of type 2 diabetes, a worldwide cause of morbidity and mortality. Today, type 2 diabetes
is controlled by a limited number of drugs and/or insulin injections, and no really effective
medical treatments exist to defeat this pathology. Stanford et al. [11] gave a new hope publishing
the full characterization of the relevant role played by low molecular weight protein
tyrosine phosphatase (LMPTP) in promoting insulin resistance and type 2 diabetes. After an
exhaustive SAR evaluation, the first bioavailable small molecule LMPTP inhibitor, namely
the N,N-diethyl-3-[3-(piperidin-1-yl)propylamino]-4-(quinolin-2-yl)benzamide, was discovered.
This compound demonstrated extraordinary potency and selectivity in modulating the LMPTP
activity in vivo. The mechanism of LMPTP inhibition was deeply investigated, enlightening the
effects of chemical inhibition of the enzyme. This approach was remarkably effective in improving
glucose tolerance, reversing high-fat diet-induced diabetes without toxicity. Since LMPTP is known
to promote heart failure and tumor growth, the newly discovered LMPTP inhibitor is a flag point
and a game-changer for the future research addressed to the development of new drugs against
human diabetes.
12. Exploring the Stability of Ligand Binding Modes to Proteins by Molecular Dynamics
Simulations: A Cross-Docking Study
Highlighted by F. Javier Luque
Docking is a fundamental approach for virtual screening of ligands and prediction of the
binding mode to their target. However, several poses can be generated for a given ligand and
identification of the correct binding mode is still challenging. Following a previous study [12],
Liu and Kokubo [13] have examined the suitability of Molecular Dynamics (MD) simulations to
discriminate between correct and decoy poses. Assuming the reliability of the classical force field,
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the underlying hypothesis is that a correct pose should be stable enough to maintain the initial pose
more steadily than decoy poses. Accordingly, they have compared the suitability of a computational
strategy that examines the structural integrity of the binding mode for a series of independent MD
simulation runs. This is performed for three distinct target proteins (thrombin, heat shock protein
90-alpha, and cyclin-dependent kinase 2), each containing docking ligands in the pose closest to the
X-ray crystallographic arrangement, and in two decoy poses chosen according to score ranking and
geometrical deviation from the crystal structure. Keeping in mind the reduced computational cost
of these computations, analysis of multiple MD equilibrium simulations may prove to be valuable
for eliminating decoy poses that cannot be distinguished exclusively by docking scores or through
complementary (i.e., pharmacophore) data, while being much less expensive than more accurate and
computationally demanding free energy calculations.
13. Elovanoids: A Novel Class of Lipid Mediators Necessary for Photoreceptor Cell Integrity
Highlighted by George Kokotos
Lipids are the major constituents of cell membranes and the most efficient source of energy.
However, it is now fully recognized that lipids also function directly as signaling mediators.
Several families of bioactive lipids regulate a plethora of cell functions and play prominent roles
in immune regulation, inflammation and maintenance of homeostasis. Recently, oxygenated products
derived from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have attracted special
attention as a new class of pro-resolving lipid mediators including resolvins and protectins [14].
The identification of novel bioactive lipids and the understanding of their function are of fundamental
importance. Bazan’s group reported a novel class of lipid mediators, called elovanoids (ELVs),
which are necessary for neuroprotective signaling for photoreceptor cell integrity [15]. Very long chain
(≥C28) polyunsaturated fatty acids including n-3 (VLC-PUFAs,n-3) are generated from the DHA- or
EPA-derived 26 carbon fatty acid by the action of elongase ELOVL4. ELVs are oxygenated derivatives
of VLC-PUFAs,n-3. The structures, stereochemistry and bioactivity of ELVs were determined using
synthetic compounds generated by stereo-controlled organic synthesis. These findings unveil a novel
autocrine/paracrine pro-homeostatic retinal pigment epithelial cell signaling that aims to sustain
photoreceptor cell integrity and reveal potential therapeutic targets for retinal degenerations.
14. Identification and Structural Characterization of First-in-Class Small Molecule
Sirtuin 6 Activators
Highlighted by Rino Ragno
Sirtuins (Sirts) are protein deacylases that regulate metabolism and stress responses, and are
implicated in various aging-related diseases, including cancer. Small molecule activators for the human
Sirt1-7 have been proposed as chemical tools and potential therapeutics, but, with the only exception
of Sirt1 activators, drug-like activators for Sirt2-7 are still missing. In particular, Sirt6 has been reported
to contribute in modulating metabolic adaptations, DNA homeostasis, life-span extension and cancer
growth and hence pharmacological Sirt6 modulation (inhibition and activation) is thus considered
a potential treatment for cancer and aging-related pathological conditions. Recently, You et al. [16]
reported a brief series of pyrrolo[1,2-a]quinoxaline derivatives as the first synthetic Sirt6 activators,
endowed with a direct, substrate-independent binding capability to the enzyme catalytic core, and
a strong activation of Sirt6-dependent deacetylation of peptide and protein substrates. Extensive
structure-based investigation by means of chemical synthesis coupled with three-dimensional structure
determination of several Sirt6/activator complexes revealed that the compounds bind to a specific acyl
channel pocket highlighting key molecular interactions that provide the structural basis for further
development of Sirt6 activators as both tools and therapeutics. The report by You et al. [16] shed light
on the role of Sirt6 and opens new frontiers in the complicated epigenetics’ labyrinth.
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15. Aquaporin-4: A Promising Target for Treating Neurological Disorders
Highlighted by Simona Collina
Aquaporins (AQs) are a family of transmembrane proteins which manage water transport across
biological membranes and water homeostasis; therefore, they can be pursued as therapeutic targets
and the identification of related modulatory drugs is of high interest for medicinal chemists. In their
recent paper, Verkman and colleagues discuss the potential of aquaporin-4 (AQ4) as drug target
and outline the therapeutic potential of its modulators for treating neurological disorders related
to water homeostasis imbalance, such as cerebral edema. Although drugging the AQs class still
represents a challenging task, the availability of AQP4 crystal structure and the advances in screening
approaches should enhance the chances for the successful identification of small molecules acting as
AQP4 modulators. This interesting article will inspire new challenging drug discovery programs [17].
16. Copper–Alkyne Complexation Responsible for the Nucleolar Localization of Quadruplex
Nucleic Acid Drugs Labeled by Click Reactions
Highlighted by Catherine Guillou
Copper (I)-catalysed 1,3-dipolar azide-alkyne cycloaddition (CuAAC) has been widely used for
labeling biological targets in cells. Copper-free cycloaddition promoted by strained cyclooctynes
(strain-promoted azide–alkyne cycloaddition, SPAAC) is a major breakthrough in live cell imaging.
G-Quadruplex(es) (G4) are noncanonical nucleic-acid structures found in guanine-rich sequences.
They can be targeted with small molecules (G4 ligands) acting as reporters, for tracking both in vitro
and in cells. The group of M.P. Teulade–Fichou reported that the results are different when using
CuAAC or SPAAC methodologies. They demonstrated the need for great care when using CuAAC to
localize drugs in cells, and show that SPAAC gives results that are more consistent between fixed and
live cells [18].
17. Proteasome Activation by Small Molecules
Highlighted by Michael Gütschow
Enhancing the activity of the ubiquitin-proteasome system (UPS) by increasing the ubiquitin pool
or overexpressing specific ubiquitin ligases or improving the proteasome activity by low-molecular
weight compounds can reduce the toxicity induced by protein aggregates and can be of therapeutic
value in the treatment of neurodegenerative diseases. Huib Ovaa’s group, at the Netherlands
Cancer Institute, together with several collaborators have used a proteasome activity probe in a
high-throughput flow cytometry-based assay and identified compounds that increased proteasome
activity, including the p38 MAPK inhibitor PD169316 [19]. Noteworthy, inhibition of p38 MAPK
and its downstream target MK2 activates the proteasome. Thus, cellular players along the MAPK
signaling cascade involved in proteasome activation have been discovered. To examine whether
p38 inhibition can enhance the degradation of ubiquitinated proteins, a PROTAC method was
employed showing that the cereblon-promoted degradation of BRD4 could be further augmented
by preincubation with PD169316. By measuring the degradation of overexpressed α-synuclein in a
bimolecular fluorescence complementation assay, the authors showed that inhibition of the p38 MAPK
pathway and the subsequent activation of the proteasome represents a promising strategy to clear
toxic protein aggregates. This study highlights the therapeutic potential of proteasome activation by
distinct molecules.
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18. Secretome Analysis of BRCA1-Mutated Human Breast Cancer Reveals Novel Biomarkers
Highlighted by Luigi A. Agrofoglio
The existence of a differential metabolic signature for breast cancer cells based on the BRCA1
mutation-associated tumors has been discovered by Spain researchers [20]. This approach, based on
metabolomics, was to analyze and to characterize the metabolic profile of human breast cancer cell
lines and plasma samples of triple-negative hereditary breast and ovarian cancer syndrome patients
taking into account their BRCA1 genotype.
It should be emphasized that one effective source for novel cancer biomarkers is the secretome,
which contains molecules released by tumor cells into the extracellular space. The secretome could
better reflect the activity of cancer in human body fluids such as blood plasma or serum.
It was shown that the levels of adenine, N6-methyladenosine and 1-methylguanine detected in
the plasma samples of patients with BRCA1 mutations were significantly lower than those in patients
who were not carriers of this mutation.
It is believed that these biomarkers have a great potential to refine breast cancer diagnosis and
enable personalized treatments.
Conflicts of Interest: The authors declare no conflict of interest.
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